STOCK TITAN
  1. Home
  2. News
  3. OBSV

OBSV - OBSV STOCK NEWS

Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.

ObsEva SA is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, specializing in the development and commercialization of novel therapies to enhance women's reproductive and pregnancy health. Founded in 2012, ObsEva is dedicated to addressing unmet needs in reproductive medicine by focusing on innovative treatments that aim to improve fertility outcomes and manage preterm labor.

Currently, ObsEva is involved in several key projects, including their lead product linzagolix, an oral GnRH antagonist designed to treat uterine fibroids and endometriosis. This medication aims to offer significant benefits over existing treatments by providing symptom relief with fewer side effects.

ObsEva's approach is underscored by a robust pipeline and strategic partnerships with leading healthcare organizations. Financially, the company continues to navigate its path with a focus on securing funding to propel its clinical trials and regulatory submissions. Recently, ObsEva has made significant strides with positive results from their Phase 3 trials for linzagolix, putting them on track for potential market approval.

ObsEva's commitment to innovation and patient health is reflected through its continuous efforts in research and development, making significant progress in areas with high medical needs. The company's forward-looking strategy is built on scientific rigor, collaborative partnerships, and a deep understanding of women's health issues.

For more information, please contact:
General inquiries: contact@obseva.ch
Investor relations: IR@obseva.ch

ObsEva SA
Chemin des Aulx 12,
1228 Plan-les-Ouates,
Switzerland

News

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

Rhea-AI Summary
ObsEva SA (SIX: OBSN) announced the delisting of its shares from the SIX Swiss Exchange, effective May 6, 2024, with exemptions from certain listing maintenance obligations. The company's last trading day will be on May 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

ObsEva Announces Update on Board of Directors

Rhea-AI Summary
ObsEva SA announces the decision to wind down its operations and the resignation of Catarina Edfjäll from the Board. The company expresses gratitude for her contributions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Rhea-AI Summary
ObsEva SA, a biopharmaceutical company listed on the SIX Swiss Exchange, announced the winding down of its operations due to financial constraints, risking delisting. The CEO, Fabien de Ladonchamps, will oversee the process during a temporary moratorium granted by the Tribunal de première instance of Geneva.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Geneva Court Grants Temporary Moratorium to ObsEva

Rhea-AI Summary
ObsEva SA, a biopharmaceutical company, has been granted a temporary moratorium by the competent court in Geneva, Switzerland, limiting the ability of its creditors to enforce claims against the company. The moratorium will last for four months, during which a commissioner will supervise the company's activities. Dr. Ernest Loumaye, Co-Founder and Chairman of the Board, has undertaken to secure funding to finance operational expenditures. The company is engaged in advanced negotiations for a transaction related to Nolasiban, a compound developed to enhance the live birth rate in women undergoing in vitro fertilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Rhea-AI Summary
ObsEva SA (SIX: OBSN) seeks a moratorium from the competent court in Geneva, Switzerland to protect its financial position and focus on negotiations and conclusions of deals that could impact its trajectory. Dr. Ernest Loumaye intends to secure funding for operational expenditures until the completion of ongoing business development and financing discussions. The company aims to ensure the seamless continuity of its operations and maximize potential benefits from the opportunities under discussion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Organon Returns Ebopiprant to XOMA

Rhea-AI Summary
ObsEva SA announced that XOMA will be receiving full worldwide rights on ebopiprant, following the termination of the license agreement with Organon. ObsEva sold all its rights to ebopiprant to XOMA, including the license agreement and intellectual property estate. ObsEva will no longer receive contingent milestone payments from Organon, but will explore strategic and partnership options with XOMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

ObsEva Files half Year 2023 Financial Statements

Rhea-AI Summary
ObsEva SA has published its Half Year 2023 Financial Statements, which can be found on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

ObsEva Recovers Full Worldwide Rights on Nolasiban

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Annual General Meeting 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is ObsEva SA's core business?

ObsEva SA specializes in developing therapies for women's reproductive and pregnancy health.

Where is ObsEva SA headquartered?

ObsEva SA is headquartered in Plan-les-Ouates, Switzerland.

What is linzagolix?

Linzagolix is an oral GnRH antagonist developed by ObsEva to treat uterine fibroids and endometriosis.

How can I contact ObsEva for general information?

You can contact ObsEva at contact@obseva.ch for general inquiries.

How can investors get in touch with ObsEva?

Investors can reach out to ObsEva at IR@obseva.ch.

What are some recent achievements of ObsEva?

ObsEva has reported positive results from their Phase 3 trials for linzagolix, positioning them for potential market approval.

Does ObsEva have any strategic partnerships?

Yes, ObsEva collaborates with leading healthcare organizations to advance their research and development efforts.

What is the focus of ObsEva's research and development?

ObsEva focuses on innovative treatments to improve fertility outcomes and manage preterm labor.

How does linzagolix differ from existing treatments?

Linzagolix aims to provide symptom relief for uterine fibroids and endometriosis with fewer side effects compared to existing treatments.

What is ObsEva's commitment to women's health?

ObsEva is dedicated to addressing unmet needs in reproductive medicine through rigorous scientific research and innovative therapies.

Stock OBSV logo
OBSV

Nasdaq:OBSV

OBSV Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OBSV Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Plan Les Ouates